newsfilter
← Latest News
Business Wire·

Epizyme Announces Date of First Quarter 2022 Financial Results

Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call t